Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

marketwatch.com - Sumitomo Dainippon Pharma 1Q Net Y17.00B Vs Net Y11.21B
Sumitomo Dainippon Pharma 1Q Net Y17.00B Vs Net Y11.21B
MarketWatch

Sumitomo Dainippon Pharma Co. Ltd. (4506.TO) Japan 1st Quarter Ended June 30 GROUP 2026 2025 Revenue Y129.50 bln Y108.00 bln Operating Profit Y18.19 bln Y20.40 bln Net Profit Y17.00 bln Y11.21 bln Per share Earnings Y39.02 Y28.21 Results are based…

thehindu.com - The Hindu Bureau - Sun Pharma Q1 net rises 27% to ₹2,895 crore
Sun Pharma Q1 net rises 27% to ₹2,895 crore
The Hindu

Sun Pharmaceuticals Industries Ltd. for the first quarter ended June 30, 2026 reported a 27% year-n-year growth in consolidated net profit to ₹2,895 crore. Sales income at ₹15,184 crore grew 10.1%. Global Innovative Medicines sales at…

fool.com - Motley Fool Transcribing - Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript
Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript
The Motley Fool

Thursday, July 30, 2026, at 8:30 a.m. ET Vice President of Investor Relations - Josh Brodsky Chief Executive Officer - Yvonne Greenstreet Chief Financial Officer - Jeff Poulton Chief Commercial Officer - Tolga Tanguler Chief Research and…

thehindubusinessline.com - Sun Pharma on track to complete Organon transaction by Q4, says management
Sun Pharma on track to complete Organon transaction by Q4, says management
BusinessLine

Sun Pharmaceutical Industries Ltd expects to complete its $11.75 billion acquisition of US-based Organon in the fourth quarter of financial year 2027, top management with the drugmaker said, after the company shared its financial performance for…

thehindubusinessline.com - Sun Pharma posts higher quarterly profit on strong demand
Sun Pharma posts higher quarterly profit on strong demand
BusinessLine

Sun Pharmaceutical Industries reported a 27 per cent rise in quarterly profit on Friday, boosted by strong demand for its high-margin specialty medicines used to treat chronic and complex conditions. Consolidated net profit rose to ₹2,895…

fool.com - Prosper Junior Bakiny - Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target
The Motley Fool

This has been an active year in the mergers-and-acquisitions landscape across the biopharmaceutical industry. One of the more notable deals was Vertex Pharmaceuticals ' acquisition of Crinetics Pharmaceuticals for $10 billion in cash (the…

thehindubusinessline.com - Torrent Pharma to cut medical representative strength to around 9,000 this year
Torrent Pharma to cut medical representative strength to around 9,000 this year
BusinessLine

Torrent Pharmaceuticals, the flagship entity of Gujarat-based Torrent Group, plans to reduce its medical representative (MR) strength to around 9,000 from the current combined field force of 9,400 as it integrates the operations of JB Chemicals &…

thehindubusinessline.com - Strides Pharma Science Q1 PAT rises 56.7% to ₹165.5 cr
Strides Pharma Science Q1 PAT rises 56.7% to ₹165.5 cr
BusinessLine

Strides Pharma Science Ltd on Friday reported a 56.7 per cent rise in profit after tax at Rs 165.5 crore in the first quarter ended June 30, on the back of strong growth in markets excluding the US. The company had posted a profit after tax of Rs…

foreignpolicyjournal.com - Ewan Scott - Pfizer (NYSE: PFE) Offers Value And Income While Eli Lilly (NYSE: LLY) Bets On Growth In Diverging Pharma Investment Race
Pfizer (NYSE: PFE) Offers Value And Income While Eli Lilly (NYSE: LLY) Bets On Growth In Diverging Pharma Investment Race
Foreign Policy Journal

Pfizer (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) represent two sharply different investment cases within the pharmaceutical sector, appealing to entirely different types of investors. Pfizer has seen its valuation compress significantly in…

energyandcapital.com - Big Pharma and Big Tech Converge to Make the Perfect Trade
Big Pharma and Big Tech Converge to Make the Perfect Trade
Energy & Capital -

Back in 1947, researchers at Bell Labs found themselves a little stuck. For two years, a man named William Shockley had chased one theory — a “field-effect” amplifier that would replace the bulky, unreliable vacuum tube.

marketbeat.com - Vestor Capital LLC Acquires 71,688 Shares of Royalty Pharma PLC $RPRX
Vestor Capital LLC Acquires 71,688 Shares of Royalty Pharma PLC $RPRX
MarketBeat

Vestor Capital LLC boosted its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 597.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 83,688 shares of the…

marketbeat.com - Royalty Pharma PLC $RPRX Shares Sold by Empowered Funds LLC
Royalty Pharma PLC $RPRX Shares Sold by Empowered Funds LLC
MarketBeat

Empowered Funds LLC decreased its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 21.6% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 228,996 shares of the biopharmaceutical company's…

takecontrol.substack.com - Reversing Alzheimer's - The Forgotten Causes and Cures Big Pharma Buried
Reversing Alzheimer's - The Forgotten Causes and Cures Big Pharma Buried
Dr. Mercola's Censored Library (Private Membership)

It's not the mind fading; it's the neurons refusing to speak under the weight of blocked blood, stale sleep, and chemical noise. Remove the interference, and even the quietest thoughts begin to whisper again. If you're being told you can get all…

marketbeat.com - Arrowstreet Capital Limited Partnership Invests $20.92 Million in Ascendis Pharma A/S $ASND
Arrowstreet Capital Limited Partnership Invests $20.92 Million in Ascendis Pharma A/S $ASND
MarketBeat

Arrowstreet Capital Limited Partnership bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm…

thehindubusinessline.com - KS Badri Narayanan - Q1 Results Today : Bajaj Finserv, Sun Pharma, GAIL, Dixon Tech, Aether, Glenmark Q1 profit rise, Urban Company logs Q1 loss, Maruti Suzuki, ITC, IOC Q1 profit declines
Q1 Results Today : Bajaj Finserv, Sun Pharma, GAIL, Dixon Tech, Aether, Glenmark Q1 profit rise, Urban Company logs Q1 loss, Maruti Suzuki, ITC, IOC Q1 profit declines
BusinessLine

Q1 Results Today, 31st July 2026 Updates: Get real-time Q1 FY27 earnings updates, profit growth, revenue numbers and management outlook from 20 Microns, Aadhar Housing Finance, Aarti Drugs, ABB India, Sanghvi Movers. EARNINGS IMPACT TODAYGAINERS:…

Receive a Daily briefing on Pharma Industry News

Get Started